Promimic
27,1
SEK
+1,5 %
PRO
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
1 investor følger denne virksomhed
+1,5%
-20,99%
-20,29%
-20,06%
-17,13%
-12,58%
-
-
+66,44%
promimic.com
Promimic specializes in biotechnology. The company conducts research and development in surface modifications. Examples of specialist areas include surface modifications for osseointegration for orthopedic and dental implants. The main operations are in Europe and America, where research and development are conducted in-house but also through partners.
Omsætning
37,07 mio.
EBIT %
-24,6 %
P/E
-
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
First North Stockholm
PRO
Daglig lav / høj pris
27,1 / 27,9
SEK
Markedsværdi
511,98 mio. SEK
Aktieomsætning
58,7 t SEK
Volumen
2,1 t
Finanskalender
Årsrapport
25.02.2025
Større aktionærerKilde: Millistream Market Data AB
Ejer | Kapital | Stemmer |
---|---|---|
K-Svets Venture AB | 38,7 % | 38,7 % |
KDev Investments AB | 12,5 % | 12,5 % |
Chalmers Ventures AB | 6,6 % | 6,6 % |
Riepen LLC | 5,6 % | 5,6 % |
Andra AP-fonden | 5,1 % | 5,1 % |
Swedbank Robur Ny Teknik | 3,3 % | 3,3 % |
Avanza | 3,1 % | 3,1 % |
Firma Andersson och Kjellin AB | 2,3 % | 2,3 % |
Per Kjellin | 2,0 % | 2,0 % |
Martin Andersson | 2,0 % | 2,0 % |